REVA Medical Inc. Release: Early Follow-Up Imaging Assessment of ReZolve® Scaffold
10/25/2012 9:48:11 AM
SAN DIEGO, Oct. 24, 2012 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") announces that the first follow-up imaging assessment of the ReZolve® scaffold was presented during a live case session at the Transcatheter Therapeutics Conference being held this week in Miami, Florida. The images included angiography, intravascular ultrasound (IVUS), and optical coherence tomography (OCT) and were presented by Dr. Alexandre Abizaid, the Company's principal investigator for the RESTORE clinical trial, from the Dante Pazzanese Institute de Cardiologie, located in Sao Paulo, Brazil.
comments powered by